PHAXIAM Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Thibaut Fayet

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	11yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Thibaut Fayet (55 yo)

less than a year

Permanencia

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Soyer	Deputy CEO	8.7yrs	€379.72k	0.010% € 1.9k
Jérôme Bailly	Deputy CEO	4.3yrs	€247.91k	0.0063% € 1.1k
Thibaut Fayet	Chief Executive Officer	less than a year	sin datos	sin datos
Céline Breda	Chief Technology Officer	less than a year	sin datos	sin datos
Cindy Fevre	Chief Scientific Officer	1.3yrs	sin datos	sin datos
Naomi Eichenbaum	Director Investor Relations	no data	sin datos	sin datos
Anne-Cécile Fumey	Vice President of Human Resources	8.3yrs	sin datos	0.0014% € 258.8
Karine Charton	Chief Business Officer	less than a year	sin datos	0.00066% € 120.3
Pascal Birman	Chief Medical Officer	less than a year	sin datos	sin datos
Frederique Vieville	Chief Regulatory Officer	less than a year	sin datos	sin datos
Philip Lorenzi	Consultant & Member of Scientific Board	no data	sin datos	sin datos
Eric Raymond	Consultant & Member of Scientific Board	no data	sin datos	sin datos

0.9yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0QSS no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Lorenzi	Consultant & Member of Scientific Board	14.3yrs	sin datos	sin datos
Eric Raymond	Consultant & Member of Scientific Board	14.6yrs	sin datos	sin datos
Bridget Bax	Consultant & Member of Scientific Board	12.3yrs	sin datos	sin datos
Arthur Frankel	Consultant & Member of Scientific Board	12.3yrs	sin datos	sin datos
Kurt Gunter	Consultant & Member of Scientific Board	12.3yrs	sin datos	sin datos
Guy Rigaud	Board Censor	no data	sin datos	sin datos
Philippe Archinard	Independent Director	11yrs	€66.00k	0.017% € 3.1k
Gil Beyen	Vice Chairman	11yrs	€572.43k	0.0080% € 1.5k
Hilde Windels	Independent Director	9.7yrs	€51.00k	0.000020% € 3.6
Didier Hoch	Chairman of the Board	less than a year	sin datos	sin datos
Leila Nicolas	Representative Director	1.3yrs	sin datos	sin datos
Robert Sebbag	Independent Director	less than a year	sin datos	sin datos

11.0yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 0QSS son experimentados ( 10.9 años antigüedad media).

PHAXIAM Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad